Evidence from biochemical, imaging, and treatment studies suggest abnormalities of the serotonin system in autism spectrum disorders, in particular in frontolimbic areas of the brain. We used the radiotracers [ 
Introduction
Asperger's Disorder is a pervasive developmental disorder (PDD), or autism spectrum disorder (ASD), characterized by impairments in social interactions and restricted, repetitive patterns of behavior, interest, and activity (American Psychiatric Association, 1994) . In order to meet DSM-IV criteria for Asperger's Disorder, in contrast to Autistic Disorder, clinically significant delay in language development should not be present (American Psychiatric Association, 1994) , although diagnostic criteria for ASD are currently undergoing revision for the DSM-V.
Findings from challenge, treatment, biochemical, and imaging studies have suggested deficiencies in the serotonin system in ASD. In particular, early support for a role of serotonin in ASD came from challenge studies. Administration of fenfluramine, an indirect serotonin agonist, to seven adults with autism resulted in blunted prolactin release compared to control subjects, suggesting a decreased responsivity of the serotonin system (McBride et al., 1989) . When 20 adults with autism were exposed to tryptophan depletion, they demonstrated a global worsening of symptoms as well as an exacerbation of behaviors such as whirling, flapping, pacing, banging and hitting themselves, rocking and anxiety (McDougle et al., 1996) .
The most direct evidence to date of central nervous system serotonergic abnormality in autism comes from imaging studies. Chugani and colleagues used positron emission tomography (PET) imaging and radiolabelled alpha-[ 11 C]methyl-L-tryptophan to demonstrate decreased synthesis of serotonin in frontal cortex and thalamus (Chugani et al., 1997) . In a single photon emission computed tomography (SPECT) study using [ 123 I]-5-I-R91150 of eight adults with Asperger's Disorder, decreased 5-HT 2A receptor availability in patients compared to controls was observed in several cortical regions (Murphy et al., 2006) . Similar results were found in a PET study using ] nor-beta-CIT to study the serotonin transporter (SERT) in 15 children and adolescents with autism and 10 non-autistic comparison subjects. They found decreased SERT capacity in medial frontal cortex, consistent with previous reports of decreased capacity to synthesize serotonin in autism (Makkonen et al., 2008 ). Psychiatry Research: Neuroimaging 194 (2011 
